

# Accelerating an HIV Prevention Revolution: A Roadmap

Wednesday, March 9, 2011 12:00 p.m. to 4:00 p.m. Hart Senate Office Building, Room 902

## BRIEFING AGENDA

#### Moderator

#### Susan J. Blumenthal, M.D., M.P.A.

Senior Policy and Medical Advisor, amfAR, The Foundation for AIDS Research

Former Assistant Surgeon General of the United States

#### **Discussant**

### Chris Collins, M.P.P.

Vice President and Director of Public Policy, amfAR, The Foundation for AIDS Research

### Panel 1: HIV/AIDS Prevention Overview: A Roadmap

Willard Cates, Jr., M.D., M.P.H.

President, Research, FHI

**HIV Prevention Technologies Overview** 

# Ron Stall, Ph.D., M.P.H.

Professor and Chair, Department of Behavioral and Community Health Sciences

Graduate School of Public Health, University of Pittsburgh HIV Prevention in MSM: Lessons Learned to Fuel Future Progress

# Panel 2: New Advances in Prevention Technologies

# Robert Grant, M.D., M.P.H.

Gladstone Institute of Virology and Immunology, University of California, San Francisco

Protocol Chair, iPrEx clinical study

PrEP Clinical Trials Results and Future Directions for a Prevention Pill

# Zeda Rosenberg, Sc.D.

CEO, International Partnership for Microbicides New Directions in Microbicide Research

### Barney S. Graham, M.D., Ph.D.

Chief, Clinical Trials Core; Chief, Viral Pathogenesis Laboratory Vaccine Research Center

National Institute of Allergy and Infectious Diseases, NIH

New Frontiers in HIV Vaccine Development

## John T. McDevitt, Ph.D.

Brown-Wiess Professor of Bioengineering and Chemistry, Rice University

**Bio-Nano-Chip Technologies for HIV Prevention and Management** 

## Panel 3: Prevention Strategies and Policy Implications

#### Robert H. Remien, Ph.D.

Research Scientist, HIV Center for Clinical and Behavioral Studies, NY Psychiatric Institute Professor of Clinical Psychology (in Psychiatry), College of Physicians and Surgeons, Columbia University Behavior Change Prevention Strategies

#### Don Des Jarlais. Ph.D.

Director of Research, Rothschild Chemical Dependency Institute Beth Israel Medical Center Professor, Dept. of Epidemiology and Public Health, Albert Einstein School of Medicine

Harm Reduction in the US and Globally

#### **Emily Bass**

Program Director, AVAC: Global Advocacy for HIV Prevention HIV Prevention Policy Issues and Perspectives

# **Panel 4: Putting Prevention into Practice**

#### Carl Dieffenbach, Ph.D.

Director, Division of AIDS
National Institute of Allergy and Infectious Diseases, NIH
Innovative Community Models for HIV Prevention

# Grant Colfax, M.D.

Director, HIV Prevention and Research San Francisco Department of Public Health HIV Prevention and Mapping Community Viral Load

# Paul Meyer, J.D.

Chairman and President, Voxiva Inc.
HIV Prevention 2.0: Applying New Media

## Panel 5: Moving Forward: Federal and Global Actions

### Kevin Fenton, M.D., Ph.D., F.F.P.H.

Director, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention

Centers for Disease Control and Prevention (CDC) Scaling Up HIV Prevention in the U.S.

## Paul De Lay, M.D.

Deputy Executive Director, UNAIDS
Scaling Up HIV Prevention Worldwide

